Bangladesh vs Indonesia: Access to anti-retroviral drugs, male
Bangladesh
45.0%
in 2024
Indonesia
44.0%
in 2024
Bangladesh rank
125th
Indonesia rank
126th
Access to anti-retroviral drugs, male over time
- Bangladesh
- Indonesia
How they compare
Bangladesh currently reports 45.0% against 44.0% in Indonesia, a difference of 1.0%.
The two have swapped places 3 times across 25 shared years of data; in 2000 it was Indonesia ahead.
Bangladesh ranks 125th and Indonesia ranks 126th of 141 countries.
Across the 3 decades both report, Bangladesh averaged higher in 2 and Indonesia in 1.
Head to head by decade
| Decade | Bangladesh | Indonesia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.9% | 1.1% | 0.2% | Indonesia |
| 2010s | 13.0% | 11.2% | 1.8% | Bangladesh |
| 2020s | 36.4% | 31.8% | 4.6% | Bangladesh |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Bangladesh or Indonesia?
- Bangladesh, at 45.0% against 44.0% in Indonesia as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Bangladesh and Indonesia?
- 1.0%, with Bangladesh ahead.
- How many years of comparable data are there for Bangladesh and Indonesia?
- 25 years are reported by both, from 2000 to 2024.
- How do Bangladesh and Indonesia rank globally for access to anti-retroviral drugs, male?
- Bangladesh ranks 125th and Indonesia ranks 126th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.